Cambridge Epigenetix Licenses Fundamental DNA Methylation IP from Boston Children’s Hospital

Product News   Apr 28, 2017 | Original story from Cambridge Epigenetix

 
Cambridge Epigenetix Licenses Fundamental DNA Methylation IP from Boston Children’s Hospital

Anjana Rao. Credit: Cambridge Epigenetix

 
 
FURTHER INFORMATION
 
 
 

Related Product News

Purified Cancer Exosome Samples

Product News

AMSBIO has introduced a range of purified cancer exosome samples to help researchers study the role of exosomes in cancer development and metastasis.

READ MORE

Xplore Image and Data Management Platform Upgraded

Product News

Philips speeds up research and biomarker discovery with major upgrade to the Xplore image and data management platform.

READ MORE

Delivering Reproducible and Robust Separations with Increase Analytical Accuracy

Product News

Thermo Fisher Scientific announces new technologies that are designed to allow analytical chemists to obtain high-resolution separations with outstanding sensitivity and reproducibility.

READ MORE

Like what you just read? You can find similar content on the communities below.

Cancer Research Diagnostics Proteomics & Metabolomics

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE